Clinical Trials Logo

IDH1 Mutation clinical trials

View clinical trials related to IDH1 Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05406700 Recruiting - Glioma, Malignant Clinical Trials

Niraparib In Recurrent IDH 1/2 Gliomas

Start date: May 18, 2023
Phase: Early Phase 1
Study type: Interventional

This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. - This research study involves an experimental treatment called Niraparib.

NCT ID: NCT04955938 Recruiting - Clinical trials for Myeloproliferative Neoplasm

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Start date: October 29, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this research is to gather information on the safety and effectiveness of fedratinib (a drug called a "jak inhibitor" ) in combination with ivosidenib or enasidenib (two anti-cancer drugs). While all three drugs are FDA-approved for various conditions, the US Food and Drug Administration (FDA) has not approved the combination of these drugs for the treatment of rare blood cancers that present Isocitrate dehydrogenase (IDH) mutations, and therefore these drugs can only be given in a research study.